CAPR - CAPR Stock Jumps to New 2019 Highs on Positive CAP-1002 Outcomes
CAPR stock is moving up big as Capricor Therapeutics Inc (NASDAQ:CAPR) announces positive data in a rare disease indication.
Big News for CapricorCalifornia-based Capricor Therapeutics has been one of the biggest gainers today after the company released positive results from the trial of its medicine CAP-1002, which is meant for the treatment of Duchenne muscular dystrophy.
It goes without saying that it is a highly promising development for Capricor and one that could propel the company into greater heights. The trial in question is known as a HOPE-2 trial and is regarded as ...
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.